Global Recombinant Collagen Market Strategic Research Report 2026-2031

Publication ID:

NAV1026006

Publication Date:

October 19, 2026

Pages:

211

Countries:

Global [1]

The global recombinant collagen market is valued at approximately US$1,171.5 million (US$1.17 billion) in 2025 and is forecast to reach approximately US$2,232 million (US$2.23 billion) by 2031, a compound annual growth rate (CAGR) of 11.3% over 2025–2031. Recombinant collagen – human or humanized collagen produced by microbial or plant-based expression rather than extracted from animal tissue - is moving from a niche biomaterial into mainstream medical aesthetics, functional skincare and biomedical applications.

The report covers value for every segment, region and country from 2022 to 2031, with 2025 as the base year. Asia Pacific, led by China, accounts for the large majority of 2025 revenue, while North America, Europe, Latin America and Middle East & Africa are small but fast-growing from a low base. Medical aesthetics is the fastest-growing application at about 17% a year, and nine leading developers and manufacturers are profiled.

Scope of the Global Recombinant Collagen Market Strategic Research Report

This report provides market sizing in value (US$ million) across collagen-type and application segments and regional and country splits, from 2022 to 2031. It also includes growth drivers and inhibitors, regulatory landscape, competitive landscape, company profiles with SWOT analysis, Porter's Five Forces, PESTLE and SWOT analysis, and future trends.

Segment by Type

Recombinant Type III Collagen
Recombinant Type I Collagen
Recombinant Type XVII Collagen
Other Collagen Types

Segment by Application

Medical Aesthetics
Functional Skincare Products
Others (Medical Dressings, Biomaterials, Functional Foods and Wound Care)

Who Can Use This Report?

Recombinant collagen developers and manufacturers planning product, regulatory and region strategy
Medical aesthetics, dermal filler and skincare companies evaluating recombinant collagen sourcing and partnerships
Biomaterials, wound-care and functional-food companies assessing adjacent applications
Investors and analysts evaluating the sector, including cell-culture and fermentation-based collagen platforms
Regulatory, market-access and business-development teams assessing approvals and ex-China expansion

1. Executive Summary
    1.1.1 Market Definition and Measured Scope
    1.1.2 Headline Market Size and Growth Trajectory
    1.1.3 The Three to Four Strongest Growth Drivers with Quantification
    1.1.4 Segment Highlights
    1.1.5 Regional and Country Highlights
    1.1.6 Competitive Structure and Key Strategic Developments
    1.1.7 Principal Risks
    1.1.8 Closing Outlook
2. Industry Overview & Forecast
2.1 Market Definition and Scope
    2.1.1 Market Size and Historical Performance
    2.1.2 Forecast and Growth Logic
    2.1.3 Volume Analysis
    2.1.4 Value Chain and Pricing Dynamics
3. Market Segmentation by Type
3.1 Structural Overview and Confidence Framework
    3.1.1 Recombinant Type III Collagen
    3.1.2 Recombinant Type I Collagen
    3.1.3 Recombinant Type XVII Collagen
    3.1.4 Other Collagen Types (Types IV, VI and Engineered Fragments)
3.2 Comparative Analysis and Mix Shift Outlook
4. Market Segmentation by Application
4.1 Structural Overview and Segment Architecture
    4.1.1 Medical Aesthetics
    4.1.2 Functional Skincare Products
    4.1.3 Others (Medical Dressings, Biomaterials, Functional Foods and Wound Care)
    4.1.4 Comparative Assessment Across Application Segments
5. Regional Market Forecast
North America
Asia Pacific
Europe
Latin America
MEA
6. Country-Level Market Forecast
6.1 North America
    6.1.1 United States
    6.1.2 Canada
    6.1.3 Mexico
6.2 Asia Pacific
    6.2.1 China
    6.2.2 Japan
    6.2.3 South Korea
    6.2.4 Southeast Asia
    6.2.5 India
    6.2.6 Australia
    6.2.7 Rest of Asia Pacific
6.3 Europe
    6.3.1 Germany
    6.3.2 France
    6.3.3 United Kingdom
    6.3.4 Italy
    6.3.5 Russia
    6.3.6 Rest of Europe
6.4 Latin America
    6.4.1 Brazil
    6.4.2 Rest of Latin America
6.5 Middle East & Africa
    6.5.1 Egypt
    6.5.2 South Africa
    6.5.3 Israel
    6.5.4 Turkey
    6.5.5 GCC Countries
    6.5.6 Rest of MEA
7. Growth Drivers & Inhibitors
7.1 Executive Summary of Market Dynamics
7.2 Growth Drivers
    7.2.1 Accelerating Regulatory Approvals Expanding the High-Value Medical Device Segment
    7.2.2 Animal-Free Origin and Sequence Precision Meeting Evolving Consumer and Regulatory Preferences
    7.2.3 Unprecedented Manufacturing Scale-Up Driving Cost Reduction and Supply Security
    7.2.4 Government Biohealth Investment Catalysing Technology Development and Clinical Validation
    7.2.5 Ex-China Regulatory Filings Establishing International Commercial Footholds
    7.2.6 AbbVie-CollPlant Clinical Programme Creating a Western Approval Pathway
7.3 Market Inhibitors
    7.3.1 Structural Price Compression Limiting Value Growth
    7.3.2 Deceleration of Chinese Functional Skincare Growth Compressing the Core Revenue Segment
    7.3.3 Regulatory Complexity, Classification Ambiguity, and Approval Timeline Risk
    7.3.4 Limited Long-Term Clinical Evidence Relative to Established Aesthetic Medicine Comparators
    7.3.5 Concentrated Supplier and Customer Base Creating Revenue Concentration Risk
7.4 Integrated Impact Assessment
8. Key Company Profiles
8.1 Giant Biogene Holding Co., Ltd.
    8.1.1 Company Overview
    8.1.2 Key Products & Segments
    8.1.3 Financial Performance (2023–2025)
    8.1.4 Business Strategy
    8.1.5 SWOT Analysis
    8.1.6 Strategic Implications (2025–2031)
8.2 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.
    8.2.1 Company Overview
    8.2.2 Key Products & Segments
    8.2.3 Financial Performance (2023–2025)
    8.2.4 Business Strategy
    8.2.5 SWOT Analysis
    8.2.6 Strategic Implications (2025–2031)
8.3 Bloomage Biotechnology Corporation Limited
    8.3.1 Company Overview
    8.3.2 Key Products & Segments
    8.3.3 Financial Performance (2023–2025)
    8.3.4 Business Strategy
    8.3.5 SWOT Analysis
    8.3.6 Strategic Implications (2025–2031)
8.4 CollPlant Biotechnologies Ltd.
    8.4.1 Company Overview
    8.4.2 Key Products & Segments
    8.4.3 Financial Performance (2023–2025)
    8.4.4 Business Strategy
    8.4.5 SWOT Analysis
    8.4.6 Strategic Implications (2025–2031)
8.5 Jiangsu Jland Biotech Co., Ltd.
    8.5.1 Company Overview
    8.5.2 Key Products & Segments
    8.5.3 Financial Performance (2023–2025)
    8.5.4 Business Strategy
    8.5.5 SWOT Analysis
    8.5.6 Strategic Implications (2025–2031)
8.6 Jiangsu Trautec Medical Technology Co., Ltd.
    8.6.1 Company Overview
    8.6.2 Key Products & Segments
    8.6.3 Financial Performance (2023–2025)
    8.6.4 Business Strategy
    8.6.5 SWOT Analysis
    8.6.6 Strategic Implications (2025–2031)
8.7 HTL Biotechnology SAS
    8.7.1 Company Overview
    8.7.2 Key Products & Segments
    8.7.3 Financial Performance (2023–2025)
    8.7.4 Business Strategy
    8.7.5 SWOT Analysis
    8.7.6 Strategic Implications (2025–2031)
8.8 Jellatech Inc.
    8.8.1 Company Overview
    8.8.2 Key Products & Segments
    8.8.3 Financial Performance (2023–2025)
    8.8.4 Business Strategy
    8.8.5 SWOT Analysis
    8.8.6 Strategic Implications (2025–2031)
8.9 Geltor, Inc.
    8.9.1 Company Overview
    8.9.2 Key Products & Segments
    8.9.3 Financial Performance (2023–2025)
    8.9.4 Business Strategy
    8.9.5 SWOT Analysis
    8.9.6 Strategic Implications (2025–2031)
9. Competitive Landscape
9.1 Competitive Landscape Overview
    9.1.1 Market Structure and Concentration
    9.1.2 Active Participant Count and Secondary-Tier Composition
    9.1.3 Top-Five Market Share Analysis
    9.1.4 Herfindahl–Hirschman Index Assessment
    9.1.5 Competitive Intensity Rating
    9.1.6 Outlook Through 2031
9.2 Competitive Intensity Assessment
    9.2.1 Tier Structure and Revenue Ranges
    9.2.2 Tier 1: Dominant Incumbents
    9.2.3 Tier 2: Scale Challengers and Platform Holders
    9.2.4 Tier 3: Pre-Commercial and Pipeline Players
    9.2.5 Capacity vs. Demand Dynamics
    9.2.6 Pricing Environment
    9.2.7 Barriers to Entry and Exit
9.3 Key Player Strategies & Positioning
    9.3.1 Strategic Group Architecture
    9.3.2 Giant Biogene: Approval-Led Diversification from a Skincare Base
    9.3.3 Jinbo Bio: Volume Defence Under Pricing Pressure
    9.3.4 CollPlant and the Western Approval Bet
    9.3.5 HTL Biotechnology: European Platform Consolidation
    9.3.6 Jellatech, Geltor, and the Cell-Culture and Food Frontiers
    9.3.7 M&A and Partnership Activity Summary (2022–Present)
    9.3.8 R&D and Technology Investment Trends
9.4 Competitive Dynamics & Strategic Outlook
    9.4.1 The Competitive Configuration Entering the Forecast Period
    9.4.2 Emerging Competitive Threats
    9.4.3 Consolidation vs. Fragmentation Outlook
    9.4.4 Competitive Response Matrix
    9.4.5 Strategic Recommendations for 2026–2031
10. Porter's Five Forces Analysis
10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry
11. PESTLE Analysis
11.1 Political
11.2 Economic
11.3 Social
11.4 Technological
11.5 Legal
11.6 Environmental
11.7 PESTLE Summary
12. SWOT Analysis
    12.1.1 Detailed Analysis
      12.1.1.1 Strengths
      12.1.1.2 Weaknesses
      12.1.1.3 Opportunities
      12.1.1.4 Threats
    12.1.2 Strategic Implications and Priority Actions
13. Future Trends & Outlook
13.1 Overview
13.2 Trend Analysis
    13.2.1 Regulatory Pipeline Expansion and Class III Device Approvals
    13.2.2 Internationalisation and Ex-China Market Registration
    13.2.3 Western Market Entry via the AbbVie–CollPlant Programme
    13.2.4 Platform Technology Maturation
    13.2.5 Combination Products and Composite Formulation Innovation
    13.2.6 Premiumisation of Skincare and Device-Grade Cosmeceutical Positioning
    13.2.7 Channel Concentration and Clinic Chain Pricing Power Dynamics
    13.2.8 Fermentation Scale Economics and Supply Chain Localisation
13.3 Summary of Trend Assessment
13.4 Forward Outlook: 2026–2031

List of Exhibits
Exhibit 2.1: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
Exhibit 2.2: Forecast of Global (in USD Mn)
Exhibit 2.3: Forecast of North America (in USD Mn)
Exhibit 2.4: Forecast of Asia Pacific (in USD Mn)
Exhibit 2.5: Forecast of Europe (in USD Mn)
Exhibit 2.6: Forecast of Latin America (in USD Mn)
Exhibit 2.7: Forecast of Middle East & Africa (in USD Mn)
Exhibit 3.8: Forecast of Recombinant Type III (in USD Mn)
Exhibit 3.9: Forecast of Recombinant Type I (in USD Mn)
Exhibit 3.10: Forecast of Recombinant Type XVII (in USD Mn)
Exhibit 3.11: Forecast of Other types (in USD Mn)
Exhibit 4.12: Forecast of Medical Aesthetics (in USD Mn)
Exhibit 4.13: Forecast of Functional Skincare Products (in USD Mn)
Exhibit 4.14: Forecast of Others (in USD Mn)
Exhibit 6.15: Forecast of North America (in USD Mn)
Exhibit 6.16: Forecast of United States (in USD Mn)
Exhibit 6.17: Forecast of Canada (in USD Mn)
Exhibit 6.18: Forecast of Mexico (in USD Mn)
Exhibit 6.19: Forecast of Asia Pacific (in USD Mn)
Exhibit 6.20: Forecast of China (in USD Mn)
Exhibit 6.21: Forecast of Japan (in USD Mn)
Exhibit 6.22: Forecast of South Korea (in USD Mn)
Exhibit 6.23: Forecast of Southeast Asia (in USD Mn)
Exhibit 6.24: Forecast of India (in USD Mn)
Exhibit 6.25: Forecast of Australia (in USD Mn)
Exhibit 6.26: Forecast of Rest of Asia Pacific (in USD Mn)
Exhibit 6.27: Forecast of Europe (in USD Mn)
Exhibit 6.28: Forecast of Germany (in USD Mn)
Exhibit 6.29: Forecast of France (in USD Mn)
Exhibit 6.30: Forecast of United Kingdom (in USD Mn)
Exhibit 6.31: Forecast of Italy (in USD Mn)
Exhibit 6.32: Forecast of Russia (in USD Mn)
Exhibit 6.33: Forecast of Rest of Europe (in USD Mn)
Exhibit 6.34: Forecast of Latin America (in USD Mn)
Exhibit 6.35: Forecast of Brazil (in USD Mn)
Exhibit 6.36: Forecast of Rest of Latin America (in USD Mn)
Exhibit 6.37: Forecast of Middle East & Africa (in USD Mn)
Exhibit 6.38: Forecast of Egypt (in USD Mn)
Exhibit 6.39: Forecast of South Africa (in USD Mn)
Exhibit 6.40: Forecast of Israel (in USD Mn)
Exhibit 6.41: Forecast of Turkey (in USD Mn)
Exhibit 6.42: Forecast of GCC Countries (in USD Mn)
Exhibit 6.43: Forecast of Rest of MEA (in USD Mn)

Giant Biogene Holding Co. Ltd.
Shanxi Jinbo Bio-Pharmaceutical Co. Ltd.
Bloomage Biotechnology Corporation Limited
CollPlant Biotechnologies Ltd.
Jiangsu Jland Biotech Co. Ltd.
Jiangsu Trautec Medical Technology Co. Ltd.
HTL Biotechnology SAS
Jellatech Inc.
Geltor Inc.

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.